These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2567050)

  • 1. [Parkinson's disease: some physiopathologic aspects and clinical practice].
    Agid Y
    Rev Prat; 1989 Mar; 39(8):641-6. PubMed ID: 2567050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
    Melamed E
    Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
    [No Abstract]   [Full Text] [Related]  

  • 3. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Hirsch EC
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological hypotheses and therapeutic strategies for gait disorders in Parkinson's disease].
    Devos D; Bordet R; Defebvre L
    Rev Neurol (Paris); 2010 Feb; 166(2):168-77. PubMed ID: 19811797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Parkinson syndrome and cognitive disorders].
    Szirmai I; Kovács T
    Ideggyogy Sz; 2002 Jul; 55(7-8):220-5. PubMed ID: 12201229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Medicinal treatment of idiopathic Parkinson's disease].
    Klockgether T
    Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of short- and long-term L-DOPA treatment in parkinsonism: role of the surviving nigrostriatal dopaminergic neurons.
    Melamed E; Hefti F
    Adv Neurol; 1984; 40():149-57. PubMed ID: 6695591
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The place of the dopaminergic agonists in the treatment of Parkinson's disease: the view from the trenches.
    King DB
    Can J Neurol Sci; 1992 Feb; 19(1 Suppl):156-9. PubMed ID: 1349264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Levodopa and cognitive disorders in Parkinson's disease].
    Leiva-Santana C; Alvarez-Saúco M
    Rev Neurol; 2006 Jul 16-31; 43(2):95-100. PubMed ID: 16838257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.
    Riederer P; Gerlach M; Müller T; Reichmann H
    Parkinsonism Relat Disord; 2007 Dec; 13(8):466-79. PubMed ID: 17919963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA; Girotti F; Giovannini P; Parati E
    J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
    Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A
    Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.